Kinase Assays for Drug Discovery

Reaction Biology offers one of the largest portfolio of kinase assays in the industry to support discovery of new kinase inhibitors.

Discover our assays
Kinase Assays for Drug Discovery
RAS Assay Suite for Drug Discovery

Reaction Biology offers a comprehensive portfolio of RAS assay services to support discovery of new RAS inhibitors.

Discover our assays
RAS Assay Suite for Drug Discovery
Immuno-Oncology Platform

Reaction Biology's comprehensive portfolio of in vitro immuno-oncology assays and in vivo tumor models provides scientists with various platforms to test new cancer drug candidate's potency and efficacy.

Read more
Immuno-Oncology Platform
New Poster
Kinase drug discovery – 20 years after imatinib

We recently sponsored a poster published by Nature reviews drug discovery, which explores pivotal advances in kinase drug discovery and the approval of more than 70 new drugs since 2001.

Download our Poster
Kinase drug discovery – 20 years after imatinib
The In Vitro Evaluation of Safety and Toxicity (InVEST Panel)

InVEST in safety & toxicity screening to evaluate your drug's selectivity profile and potential off-target adverse effects.

Find out more
The In Vitro Evaluation of Safety and Toxicity (InVEST Panel)

Premium Drug Discovery Services

Our clients are seeking answers in their quest to discover effective treatments for patients. Finding these answers is our mission as a CRO. Our method is to accelerate the drug discovery process with the widest possible range of assays and services but also to maintain an integrated view of the journey to a lead drug candidate. We strive to provide excellent data, delivered in a timely, collaborative manner by outstanding scientists. Who are we? We’re your partner.

About us

Let’s Discover Together.

Integrated Drug Discovery

The Reaction Oncology Platform.

Target-Specific Assays

Assays for drug screening against 1000+ targets

Cell-Based Assays

Drug testing in the physiological environment of intact cells.

Biophysical Assays

Elucidate the mechanism of action of drug candidates on a molecular level.

In Vivo Pharmacology

Tumor models to reliably test the potency of drug candidates in mice.

Immuno-Oncology Platform

Supporting your immunotherapy drug discovery.

ADME & Safety

Pharmacological testing to provide a basis for preclinical candidate selection.

Biomarker Discovery

Identify the genomic and proteomic signature of a drug response.

What people are saying

Reaction Biology Europe has provided their services for several projects with us, including establishing an orthotopic tumor model and PK/PD studies. I was very impressed, not only by their level of expertise and professionalism but also by their enthusiasm and drive to deliver. The insightful advice they provide has been instrumental to our successes and their collegial and “can do” attitude make them a pleasure to team up with!

Prof Matthias Klugmann
Scientific Expert at Boehringer-Ingelheim

You are our No 1 CRO for cancer studies and while we know that we are sometimes a bit difficult (many protocol changes on short notice) we appreciate even more your flexibility and your motivation and attitude to deliver correct results. We look forward to many more studies with you to come.

Dr Claus Kremoser
Cofounder and Chairman of Supervisory Board

I have worked with Reaction Biology Europe and Reaction Biology Corp. for more than 5 years on several interesting projects. These have ranged from routine enzyme screening to more complex kinome-scan and in-cell target engagement work. The results of these endeavors have led to a series of top-tier publications. This coupled with exceptional customer service means I have no hesitation to recommend Reaction Biology Corp. and Reaction Biology Europe as research partners.

Dr Christopher Asquith
Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill

Reaction Biology Europe has provided their service for numerous projects with us, especially on multiple kinase assays (under the name ProQinase) which have guided our way through drug development. I was very impressed not only by their level of expertise and professionalism but also by their enthusiasm and drive to deliver without delay. The insightful advice they provide has been instrumental to our successes, and the reproducibility, quality, and reporting of the results have been outstanding throughout the many years we have been working together.

Dr Laurent Meijer
Chair & Chief Scientific Officer at Perha Pharmaceuticals & ManRos Therapeutics

We have worked with Reaction Biology Europe for 3 years on in vivo drug development assays. They have provided their services from routine PK through efficacy and custom BLI studies in tumor models, consistently generating high-quality results that guided our development process. Their expertise, responsiveness, and professionalism make Reaction Biology stand out from among the usual CROs, and we are happy to recommend them as research partners.

Dr Oliver Thorn-Seshold
Department of Pharmacy, Ludwig-Maximilian's University of Munich (LMU)
Read all client testimonials

Meet Us at Our Next Event

London, UK
London, UK
-

Tumour Models London

Meet us in London

Schedule a meeting

Latest News

Reaction Biology to Present Data at AACR 2023 Showcasing Expansive Capabilities in Immuno-Oncology Drug Discovery and Development

~ New Data will be Presented on the Company’s Innovative Assay Technologies, Preclinical Profiling Models and Proprietary Screening Platforms ~

~ Reaction Biology will be at Booth #1527 in the AACR 2023 Exhibit Hall ~

Read more

Reaction Biology Selected for Participation in National Chemical Biology Consortium to Support Drug Discovery Utilizing Surface Plasmon Resonance (“SPR”) Technology

Reaction Biology Corporation (“Reaction”), an industry-leading provider of drug discovery services, today announced that it has been selected to participate as a Specialized Center in the Chemical Biology Consortium (CBC), the discovery engine of the National Cancer Institute (NCI) Experimental Therapeutics (NExT) Program, administered through the Frederick National Laboratory for Cancer Research (FNLCR).

Read more

Reaction Biology Acquires Bioassay GmbH Increasing Large Molecule Capabilities Within Its Robust Portfolio of Drug Discovery and Development Services

~ Bioassay GmbH, an Independent Contract Laboratory, Specializes in the Development, Validation and Routine Performance of Bioanalytical Assays ~
~Transaction Includes Acquisition of Bioassay GmbH Subsidiary, Peptide Specialty Laboratories GmbH, a Provider Specializing in the Synthesis and Production of Customized Peptides and Specific Antibodies~

Read more